Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 2/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593222 | 0.96 | JAK2 (0.34) | ACKR3FAAHMMP1MMP9MMP13 | |
| SCHEMBL592322 | 0.89 | PRKAA2 (0.35) | ACKR3FAAHMMP1MMP9MMP13 | |
| SCHEMBL594333 | 0.89 | FAAH (0.35) | FAAHMMP1MMP9MMP13ADAM17 | |
| SCHEMBL594222 | 0.89 | MLNR (0.35) | FAAHMMP1MMP9MMP13ADAM17 | |
| SCHEMBL593414 | 0.88 | POLB (0.34) | ACKR3FAAHMMP1MMP9MMP13 | |
| SCHEMBL13031014 | 0.88 | BACE1 (0.36) | ACKR3FAAHBACE1KCNH2MCHR1 | |
| SCHEMBL593704 | 0.88 | ALDH1A1 (0.39) | FAAHBACE1KCNH2 | |
| SCHEMBL592547 | 0.88 | JAK2 (0.36) | MMP1MMP9MMP13ADAM17JAK2 | |
| SCHEMBL13031022 | 0.87 | BACE1 (0.39) | JAK2JAK1AXLMERTKBACE1 | |
| SCHEMBL5478973 | 0.86 | KCNH2 (0.38) | ACKR3FAAHBACE1KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2063889-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030412-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | GPR6 2206/4885ACKR3 4450/4885HRH2 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.